The discussion highlighted the company's expansion into pharmaceutical development with NB4168, a novel NAD analog targeting rare genetic diseases and accelerated aging. The team emphasized strong scientific leadership, a robust safety profile for NB4168, and a continued focus on profitability and responsible growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.